Previous 10 | Next 10 |
Biostage, Inc. (BSTG) Q3 2022 Earnings Conference Call November 15, 2022 9:00 AM Company Participants David Green - Interim Chief Executive Officer Joe Damasio - Chief Financial Officer Conference Call Participants Presentation Operator Gr...
Biostage press release ( OTC:BSTG ): Q3 GAAP EPS of -$0.10. For further details see: Biostage GAAP EPS of -$0.10
Biostage Reports Corporate Highlights and Third Quarter Financial Results PR Newswire HOLLISTON, Mass. , Nov. 14, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful fir...
Biostage Schedules Conference Call and Webcast for Q3 2022 Results PR Newswire HOLLISTON, Mass. , Nov. 10, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-...
Biostage ( OTC:BSTG ), which is developing regeneration therapies for damaged organs, has disclosed terms for a proposed $6M public offering and uplisting to Nasdaq. The Mass.-based biotech company said in a filing that it is looking at offering 1M units for the assumed pric...
Biostage Receives U.S. Patent for Cellularized Patch-Based Scaffolds for Organ Repair PR Newswire Extends core IP from tubes to patches and from regenerating the esophagus after esophagectomy to treating fistulas and strictures anywhere in the GI tract including the es...
Biostage ( OTC:BSTG ) said Monday it appointed Joseph Damasio as CFO . Damasio's recent experience includes CFO, VP finance and controller roles at Inhibikase Therapeutics, Cue Biopharma and Pressure Biosciences. For further details see: Biostage appoints Joseph Dama...
Biostage Announces Appointment of New Chief Financial Officer PR Newswire HOLLISTON, Mass. , Aug. 8, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human e...
Biostage press release ( OTC:BSTG ): Q2 GAAP EPS of -$0.12. As of June 30, 2022, the Company had operating cash on-hand of $4.6 million. For further details see: Biostage GAAP EPS of -$0.12
Biostage Reports Corporate Highlights and Second Quarter Financial Results PR Newswire HOLLISTON, Mass. , Aug. 4, 2022 /PRNewswire/ --Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful fir...
News, Short Squeeze, Breakout and More Instantly...
Entered into securities purchase agreements with accredited investors for a $1.5 million private investment in public equity (PIPE) financing. The transaction closed on April 15, 2024. Received $0.5 million in convertible debt from Company’s CEO in February 2024. Hollisto...
Established a Research Collaboration with the McGowan Institute for Regenerative Medicine at the University of Pittsburgh to Study the Repair and Regeneration of the Colon following Colectomy Established a Collaboration with Hugh Taylor, MD, chair of Obstetrics, Gynecology & Reproduct...
Holliston, MA, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate o...